Pancreatic cancer — biological & vaccine options

10 open options

TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
CD318-CAR-T cells
TRIALPHASE1 / PHASE2RECRUITING
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Low-dose Radiotherapy · Pucotenlimab · AG regimen — 1 site
TRIALPHASE1 / PHASE2RECRUITING
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Autologous dual-target CAR-T cells selected from the predefined target library. · Fludarabine · Cyclophosphamide — 1 site
TRIALPHASE1 / PHASE2RECRUITING
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) · EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1) · Lymphodepleting chemotherapy (Flu/Cy) — 1 site
TRIALPHASE1RECRUITING
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NT-112: Autologous, engineered T Cells targeting KRAS G12D · AZD0240: Autologous, engineered T Cells targeting KRAS G12D — 18 sites
TRIALPHASE1NOT_YET_RECRUITING
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
TCR-T cells — 2 sites
TRIALPHASE1RECRUITING
Autologous CAR-T Cells Targeting B7-H3 in PDAC
iC9-CAR.B7-H3 T cell infusion — 1 site
TRIALPHASE2RECRUITING
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Durvalumab · Gemcitabine · Nab paclitaxel — 1 site
TRIALPHASE1RECRUITING
CAR-NK Cells (CL-NK-003) in Pancreatic Cancer
CL-NK-003 — 1 site
TRIALPHASE2RECRUITING
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Mirabegron — 1 site

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.